2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2016

2:30PM-4:00PM: Abstract Number: 920

Autoantigen-Specific T Cell and Antibody Reactivity to a Human Gut Commensal in Antiphospholipid Syndrome

B Cell Biology and Targets in Autoimmune Disease I

2:30PM-4:00PM: Abstract Number: 917

B Cells Inhibit Osteoblast Differentiation in Inflammatory Arthritis

B Cell Biology and Targets in Autoimmune Disease I

2:30PM-4:00PM: Abstract Number: 939

Circulating IgG4 Antibody Secreting Cells Are Better Biomarker of Disease Activity Compared to Serum IgG4 Levels in Patients with IgG4-Related Disease

Miscellaneous Rheumatic and Inflammatory Diseases I

2:30PM-4:00PM: Abstract Number: 965

Clinical and Serologic Variables Associated with Renal Response Among Lupus Nephritis Phase III Trial Patients Treated with Standard of Care Immunosuppression

Systemic Lupus Erythematosus – Clinical Aspects and Treatment I: Nephritis

2:30PM-4:00PM: Abstract Number: 984

Clinical Characteristics of Inflammatory Myopathies Associated with Cancer: A Report from the Remicam Registry

ARHP I: Exemplary Abstracts

2:30PM-4:00PM: Abstract Number: 973

Clinical Characterization of Patients with World Health Organization Group 2 Pulmonary Hypertension in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics I

2:30PM-4:00PM: Abstract Number: 946

Comparative Effectiveness of Second-Line Treatment Strategies for Lyme Arthritis in Children

Pediatric Rheumatology – Clinical and Therapeutic Aspects I: Juvenile Arthritis

2:30PM-4:00PM: Abstract Number: 953

Comparison of 10-Years Disease Outcomes of Rheumatoid Arthritis Patients with Continued Low Disease Activity on Methotrexate with or without Initial Combination Therapy with Infliximab or Prednisone and Sulfasalazine

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy I: Treatment Strategies

2:30PM-4:00PM: Abstract Number: 949

Comparison of Treatment Response, Remission Rate and Drug Adherence in Polyarticular Juvenile Idiopathic Arthritis Patients Treated with Etanercept, Adalimumab or Tocilizumab

Pediatric Rheumatology – Clinical and Therapeutic Aspects I: Juvenile Arthritis

2:30PM-4:00PM: Abstract Number: 925

Complement C5a Receptor Is the Key Initiator of Neutrophil Adhesion and Inflammation in Immune Complex-Induced Arthritis

Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis I

2:30PM-4:00PM: Abstract Number: 974

Diffuse Scleroderma, Male Sex, and Myopathy Are Associated with Severe Gastrointestinal Dysmotility in Scleroderma

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics I

2:30PM-4:00PM: Abstract Number: 937

Distal Interphalangeal Joint Erosions Assessed By HR-pQCT in Patients with Psoriatic Onycholysis

Imaging of Rheumatic Diseases I: Advanced Imaging in RA and Spondyloarthritides

2:30PM-4:00PM: Abstract Number: 981

Effectiveness of a Six-Week Hand Osteoarthritis Program in a Primary Care Setting

ARHP I: Exemplary Abstracts

2:30PM-4:00PM: Abstract Number: 985

Effectiveness of a Web-Based Personalized Rheumatoid Arthritis Risk Tool with or without a Health Educator for Knowledge of RA Risk Factors

ARHP I: Exemplary Abstracts

2:30PM-4:00PM: Abstract Number: 954

Effectiveness of Different Dosages of Retreatment of Rituximab in Combination with Leflunomide: Results from a Multicenter Randomized Placebo Controlled Investigator Initiated Clinical Trial in Active Rheumatoid Arthritis (Amara-Study

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy I: Treatment Strategies

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].